Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on LinkedIn:
“Happy Clinical Trials Day!
Honored to work alongside an incredible team of investigators dedicated to ending cancer. Grateful for the innovation, perseverance, and hope that fuels every study & every clinical trial.
Looking forward to ASCO25.”
More posts featuring Vivek Subbiah.